Based on the Acurx Pharmaceuticals LLC stock forecast from 1 analysts, the average analyst target price for Acurx Pharmaceuticals LLC is USD 12.00 over the next 12 months. Acurx Pharmaceuticals LLC’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Acurx Pharmaceuticals LLC is Bearish, which is based on 1 positive signals and 7 negative signals. At the last closing, Acurx Pharmaceuticals LLC’s stock price was USD 0.40. Acurx Pharmaceuticals LLC’s stock price has changed by +7.75% over the past week, -6.78% over the past month and -80.21% over the last year.
No recent analyst target price found for Acurx Pharmaceuticals LLC
No recent average analyst rating found for Acurx Pharmaceuticals LLC
Company Overview Acurx Pharmaceuticals LLC
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York. Read Less
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical t...Read More
Frequently Asked Questions About Acurx Pharmaceuticals LLC (ACXP) Stock
Based on ratings from 1 analysts Acurx Pharmaceuticals LLC's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on ACXP's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for ACXP is USD 12.00 over the next 12 months. The maximum analyst target price is USD 12 while the minimum anlayst target price is USD 12.
Unfortunately we do not have enough data on ACXP's stock to indicate if its overvalued.
The last closing price of ACXP's stock was USD 0.40.
The most recent market capitalization for ACXP is USD 9.00M.
Based on targets from 1 analysts, the average taret price for ACXP is projected at USD 12.00 over the next 12 months.
This means that ACXP's stock price may go up by +2,887.30% over the next 12 months.
We can't find any ETFs which contains Acurx Pharmaceuticals LLC's stock.
As per our most recent records Acurx Pharmaceuticals LLC has 4 Employees.
Acurx Pharmaceuticals LLC's registered address is 259 Liberty Avenue, Staten Island, NY, United States, 10305.
You can get more information about it from Acurx Pharmaceuticals LLC's website at https://www.acurxpharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Acurx Pharmaceuticals LLC (ACXP) Stock
Based on ratings from 1 analysts Acurx Pharmaceuticals LLC's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on ACXP's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for ACXP is USD 12.00 over the next 12 months. The maximum analyst target price is USD 12 while the minimum anlayst target price is USD 12.
Unfortunately we do not have enough data on ACXP's stock to indicate if its overvalued.
The last closing price of ACXP's stock was USD 0.40.
The most recent market capitalization for ACXP is USD 9.00M.
Based on targets from 1 analysts, the average taret price for ACXP is projected at USD 12.00 over the next 12 months.
This means that ACXP's stock price may go up by +2,887.30% over the next 12 months.
We can't find any ETFs which contains Acurx Pharmaceuticals LLC's stock.
As per our most recent records Acurx Pharmaceuticals LLC has 4 Employees.
Acurx Pharmaceuticals LLC's registered address is 259 Liberty Avenue, Staten Island, NY, United States, 10305.
You can get more information about it from Acurx Pharmaceuticals LLC's website at https://www.acurxpharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ACXP !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
